Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AZD6094 (Volitinib) in MET-amplified advanced gastric adenocarcinoma as third-line therapy
KCT0004070Phase 2Recruiting
- Sponsor
- Samsung Medical Center
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of savolitinib in gastric adenocarcinoma, sponsored by Samsung Medical Center. Started Feb 2016; status: recruiting.
02
Drugs
savolitinib
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on KCT0004070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004070.